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Abstract
We investigate the dynamics of cancer initiation in a mathematical model with
one driver mutation and several passenger mutations. Our analysis is based
on a multi type branching process: We model individual cells which can either
divide or undergo apoptosis. In case of a cell division, the two daughter cells
can mutate, which potentially confers a change in fitness to the cell. In con-
trast to previous models, the change in fitness induced by the driver mutation
depends on the genetic context of the cell, in our case on the number of pas-
senger mutations. The passenger mutations themselves have no or only a very
small impact on the cell’s fitness. While our model is not designed as a specific
model for a particular cancer, the underlying idea is motivated by clinical and
experimental observations in Burkitt Lymphoma. In this tumor, the hallmark
mutation leads to deregulation of the MYC oncogene which increases the rate
of apoptosis, but also the proliferation rate of cells. This increase in the rate of
apoptosis hence needs to be overcome by mutations affecting apoptotic path-
ways, naturally leading to an epistatic fitness landscape. This model shows a
very interesting dynamical behavior which is distinct from the dynamics of can-
cer initiation in the absence of epistasis. Since the driver mutation is deleterious
to a cell with only a few passenger mutations, there is a period of stasis in the
number of cells until a clone of cells with enough passenger mutations emerges.
Only when the driver mutation occurs in one of those cells, the cell population
starts to grow rapidly.
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1. Introduction
Tumors develop by accumulating different mutations within a cell, which
affect the cell’s reproductive fitness (Armitage and Doll, 1954; Lengauer et al.,
1998; Hanahan and Weinberg, 2000; Michor et al., 2004; Wodarz and Komarova,
2005; Sjo¨blom et al., 2006; Greenman et al., 2007; Wood et al., 2007; Jones
et al., 2008; Attolini and Michor, 2009; Parmigiani et al., 2009; Gerstung and
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Beerenwinkel, 2010). As Bozic et al. (2010), we refer to the fitness of a mutated
cell as the ratio between a cell’s rate to proliferate and the cell’s rate of apoptosis
compared to wild type cells. The higher the fitness, the more likely it is for the
cell to proliferate. For high fitness values, the population of cells growths very
fast and stochastic effects play a minor role. In our model, this can be thought
of as the formation of a tumor.
However, many mutations have no impact on the cell’s fitness, e.g. mutations
not affecting coding or regulatory sequences. Other mutations may lead to a
fitness disadvantage, which implies that the cell’s risk of apoptosis is higher than
its chance of proliferation. However, the same mutations in combination with
other mutations within the same cell might lead to a large fitness advantage.
We were motivated by genetic studies in Burkitt Lymphoma, a highly ag-
gressive tumor, where a single genetic alteration has an impact on a wide range
of other genes, some of them affect cell growth while others induce apoptosis.
More specifically, a chromosomal translocation between the MYC protoonco-
gene on chromosome 8 and one of three immunoglobulin (IG) genes is found
in almost every case of Burkitt Lymphoma (Richter et al., 2012; Allday, 2009;
Hummel et al., 2006; Sander et al., 2012). This leads to deregulated expression
of the MYC RNA and in consequence, to deregulated MYC protein expression.
The MYC protein acts as a transcription factor and has recently been shown
to be a general amplifier of gene expression (Nie et al., 2012; Lin et al., 2012),
targeting a wide range of different genes. Most importantly, MYC expression
induces cell proliferation. In Burkitt Lymphoma, the IG-MYC fusion is evi-
dently the key mutation for tumorigenesis (Salaverria and Siebert, 2011; Zech
et al., 1976; Schmitz et al., 2014; Campo, 2012). However, MYC plays also a
key role in inducing apoptosis (Pelengaris et al., 2002; Wang et al., 2011; Hoff-
man and Liebermann, 2008). Thus, the IG-MYC translocation alone would
lead to cell death. Therefore, the IG-MYC translocation has to be accompa-
nied by additional mutations, which deregulate the apoptosis pathways, such
as mutations affecting e.g. TP53 or ARF (Richter et al., 2012; Allday, 2009;
Sander et al., 2012). These additional mutations have probably only little di-
rect impact on the cell’s fitness, since apoptosis is rare. Hence, these mutations
cannot be considered as primary driver mutations in the context of Burkitt
Lymphoma. However, in combination with the MYC mutation these additional
mutations decrease the apoptosis rate. Consequently, the cells proliferate fast
and the population grows accordingly, leading to tumorigenesis. Because all
cells carry the MYC mutation in Burkitt Lymphoma, but fast growth does not
start immediately with that mutation, it seems to confer its large fitness advan-
tage only in a certain genetical context. Thus, interactions between different
mutations may crucially affect the dynamics of cancer progression. Due to the
fact that those additional mutations do not confer a direct fitness advantage,
they cannot be considered as driver mutations. Nevertheless, at least some of
them are necessary in order for the MYC mutation to become advantageous for
the cell. Therefore, they cannot be regarded as true passenger mutations, ei-
ther. Throughout this manuscript, we therefore call these additional mutations
“secondary driver mutations”.
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Besides Burkitt Lymphoma, epistatic effects in cancer initiation seem also
to be relevant for other cancers. For example, we can think of the inactivation
of a tumor suppressor gene discussed by Knudson in the context of retinoblas-
toma (Knudson, 1971). This inactivation is neutral for the first hit but highly
advantageous for the second hit, and can hence be viewed as an interaction
of genes (Nowak et al., 2002, 2004; Vogelstein and Kinzler, 2004; Iwasa et al.,
2005). Another case is found in lung carcinomas, where activation of each of
two oncogenes (SOX2 and PRKCI) alone is insufficient, but in concert they
initiate cancer (Justilien et al., 2014). In other cases, there is clear evidence for
sign epistasis: The ras family of proto-oncogenes is also discussed to underlie
epistatic effects. Amplification of ras leads to senescence in the cell. Neverthe-
less, ras is a well known oncogenic driver gene. Hence, the ras mutation needs
to be accompanied by other mutations (Elgendy et al., 2011; Serrano et al.,
1997). Moreover, the difficulty to distinguish between drivers and passengers
(Futreal, 2007; Fro¨hling et al., 2007) suggests that for a full understanding of
cancer initiation it is insufficient to think of these two types of mutations only.
So far, most models have focused on the idea that passenger mutations have
no effect or only a little effect, whereas each driver mutation increases the fitness
of the cell (Michor et al., 2004; Beerenwinkel et al., 2007; Bozic et al., 2010; Ger-
stung and Beerenwinkel, 2010; Antal and Krapivsky, 2011; Reiter et al., 2013;
Durrett et al., 2010; Datta et al., 2013). Other models focus on the neutral ac-
cumulation of mutations (Durrett et al., 2009; Luebeck and Moolgavkar, 2002).
Moreover, different mutations are typically treated as independent, which is a
strong assumption that will often not be fulfilled. In our model, mutations are
interacting in an epistatic way (Wolf et al., 2000): the change in fitness induced
by the driver mutation depends strongly on the genetic environment, i.e. in our
case on the number of secondary driver mutations that are present in that cell.
In addition we assume that the secondary driver mutations alone have almost
no fitness advantage. Such a dependence between mutations can strongly affect
the dynamics of cancer initiation. In evolutionary biology, epistatic systems are
often analyzed regarding the structure or ruggedness of the landscape and the
accessibility of different pathways (Weinreich et al., 2005; Franke et al., 2011;
Szendro et al., 2013). The experimental literature also studies which factors
can lead to epistasis (de Visser et al., 2011; Szappanos et al., 2011). Here, we
are interested in the dynamics of such an epistatic model, which we illustrate
by stochastic, individual based simulations. In addition, we derive analytical
results for the average number of cells with different combinations of mutations
and find a good agreement with the average dynamics in individual based com-
puter simulations. Furthermore, we discuss the computation of the waiting time
until cancer initiation. Our results show that the dynamics in such systems of
epistatic interactions are distinct from previous models of cancer initiation (Mi-
chor et al., 2004; Beerenwinkel et al., 2007; Bozic et al., 2010; Gerstung and
Beerenwinkel, 2010; Antal and Krapivsky, 2011; Reiter et al., 2013), which may
have important consequences for the treatment of such cancers. While in pre-
vious models there is a steady increase in growth with every new mutation, in
our model there is a period of stasis followed by a rapid tumor growth.
3
Of course, the biology of Burkitt Lymphoma is much more complex than
modelled herein. To make the model more realistic one would have to distin-
guish between the different secondary driver mutations, since different genes
contribute differently to the cells fitness, especially in a cell where the IG-MYC
fusion is present. Our model is not aimed to realistically describe such a situ-
ation in detail. Instead, we focus on the extreme case of the so called all-or-
nothing epistasis (Barrick and Lenski, 2013; Meyer et al., 2012) to illustrate its
effect on the dynamics of cancer initiation. As there is no theoretical analysis of
epistatic effects in cancer initiation so far, a well understood minimalistic model
seems to be necessary in order to illustrate the potential impact of epistasis
on cancer progression. Our minimalistic model clearly shows that epistasis can
lead to a qualitatively different dynamics of cancer initiation.
2. Mathematical model
We analyze cancer initiation in a homogenous population of initially N cells
with discrete generations. In every generation, each of the N cells can either
die or divide. If a cell divides, its two daughter cells can mutate with mutation
probabilities µD for the driver mutation and µP for secondary driver mutations
(where the P indicates that these would be called passenger mutations in closely
related models). In principle, we could drop the assumption that these two mu-
tation probabilities are independent on the cell of origin, but this would lead
to inconvenient notation. We neglect back mutations and multiple mutations
within one time step, because their probabilities are typically very small. Fig-
ure 1 summarizes the possible mutational pathways of the model. The variables
xi,j denote the number of cells with or without the primary driver mutation
(i = 1 or i = 0 respectively), and j secondary driver mutations.
Number of Secondary Driver Mutations
No Driver
0
x0,0
x1,0
1 2 j
x0,1 x0,2 x0,j
x1,1 x1,2 x1,j
…
...
...Driver
μD μD μD μD μD
μP μP μP μP
Fi
tn
es
s
neutral deleterious advantageous
x0,0 x0,1 x0,2 x0,3 x0,4
x1,0 x1,1 x1,2 x1,3 x1,4
Figure 1: Mutational pathways of the model. Left: The entries xi,j denote the number of cells
with or without the primary driver mutation (i = 1, or i = 0 respectively), and j secondary
driver mutations. Right: Cells with only secondary driver mutations have neutral or nearly
neutral fitness. The fitness of cells with the primary driver mutation depends on the number
of secondary driver mutations within the cell, leading to an epistatic fitness landscape.
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A cell’s probability for apoptosis and proliferation depends on the presence of
the primary driver mutation and on the number of secondary driver mutations
it has accumulated. For cells with no mutations, the division and apoptosis
probabilities are both equal to 12 . This implies that the number of cells is
constant on average as long as no further mutations occur. We assume that
the initial number of cells is high and thus we can neglect that the population
would go extinct (Haccou et al., 2005). For our parameter values, the expected
extinction time of our critical branching process exceeds the average life time of
the organism by far.
For cells without the primary driver mutation, each secondary driver muta-
tion leads to a change in the cell’s fitness by sP. For cells with the primary driver
mutation, the fitness advantage obtained with each secondary driver mutation
is sDP. The driver mutation increases both the apoptosis rate and the prolif-
eration rate. The increase in the apoptosis rate is sD− and the increase in the
division rate is sD+ . With these parameters, the proliferation rate b0,j for cells
with j secondary driver mutations but without the primary driver mutation is
b0,j =
1
2
(1 + sP)
j , (1)
whereas the proliferation rate b1,j for such cells with the primary driver mutation
is
b1,j =
1
2
· 1 + s
+
D
1 + s−D
(1 + sDP)
j . (2)
The apoptosis rates, denoted as d0,j and d1,j are simply one minus the prolifer-
ation rate
d0,j = 1− 1
2
(1 + sP)
j ,
d1,j = 1− 1
2
· 1 + s
+
D
1 + s−D
(1 + sDP)
j .
(3)
3. Results
3.1. Simulations
Mutations occur at fixed rates µD and µP for primary and secondary drivers,
respectively. For a long time, the overall fitness does not increase noticeably.
For sP = 0, it stays on average constant. Hence, the total number of cells stays
approximately constant. Only when a cell with enough secondary driver muta-
tions and also the primary driver mutation arises, the cell’s fitness is increased
substantially beyond the fitness of other cells and its chance of proliferation is
significantly increased. At that point, the total number of cells starts to increase
rapidly, see Figure 2. In models presented in literature so far, the cell’s fitness
is increased independently with every (driver) mutation (see e.g. Beerenwinkel
et al., 2007; Bozic et al., 2010). Although the total number of cells increases
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exponentially, these models do not find a sudden burst in the number of cells.
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Figure 2: The dynamics of the total number of cells. Initially, the total cell count increases
only marginally but at some point, a combination of primary and secondary driver mutations
within one cell with a large fitness benefit arises and leads to rapid exponential proliferation
(parameters: Initial number of cells N = 500000, secondary driver fitness advantage sP =
10−5, the primary driver fitness advantage sD+ = 0.05, primary driver disadvantage sD− =
0.1, advantage of a secondary driver mutation in the presence of the primary driver mutation
sDP = 0.015, mutation rates for secondary driver mutations µP = 2 · 10−5, mutation rate for
the primary driver mutation µD = 5 · 10−6).
In Figure 3, the total number of cells is subdivided into the number of cells with
different numbers of mutations. The left panel presents the cells that have not
acquired the primary driver mutation, the right one shows cells with the pri-
mary driver mutation. Cells with the primary driver mutation, but not enough
secondary driver mutations, arise occasionally, but those cells die out quickly
again – thus, their average abundance is small. Cells without the primary driver
mutation do not die out, they also do not induce fast growth, cf. Figure 3. Only
cells that have obtained enough secondary driver mutations and in addition ac-
quire the primary driver mutation, divide so quickly that the population size
increases rapidly.
The parameters in our figures have been chosen such that a cells acquires a
substantial growth advantage once the primary driver mutation co-occurs with
4 secondary driver mutations. This event can occur at any time and hence, in
some simulation the number of cells can increase very early, whereas in other
simulations the number of cells does not undergo fast proliferation for many
generations. Consequently, the rate of progression has an enormous variation.
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Figure 3: The dynamics of the number of cells with different numbers of mutations in a
single simulation. Top: The number of cells without any mutation decreases slightly, whereas
the number of cells with secondary driver mutations, but no primary driver mutation, slowly
increases. Bottom: While a small number cells with the primary driver mutation is present
from the beginning, at first these primary driver mutations are not accompanied by sufficiently
many secondary driver mutations to compensate the disadvantage arising from the primary
driver. Only when a primary driver mutation is co-occurring with enough secondary driver
mutations (in this case four), the number of cells with the primary driver starts to increase
rapidly. (parameters: N = 500000, sP = 10
−5, sD+ = 0.05, sD− = 0.1, sDP = 0.015,
µP = 2 · 10−5, µD = 5 · 10−6)
For the parameters from our figures, the time at which rapid proliferation oc-
curs varied between ≈ 9300 and ≈ 63000 generations in 500 simulations. The
distribution of these times is discussed in more detail below.
3.2. Analytical results
3.2.1. Average Number of Cells
We can calculate the average number of cells with a certain number of muta-
tions at a given generation t. The number of cells which do not have the primary
driver mutation and k secondary driver mutations (i.e. x0,k(t)) changes on av-
erage by means of the cell’s fitness and it decreases by the mutation rate
x0,k(t) = (1− (µP + µD))(1 + sP)kx0,k(t− 1) + µP(1 + sP)k−1x0,k−1(t− 1),
(4)
where x0,−1(t) ≡ 0. The solution of Equation (4) for sP 6= 0, i.e. if the secondary
driver mutations are not neutral, is
x0,k(t) = Nµ
k
P(1− (µD + µP))t−k(1 + sP)k(k−1)/2
k−1∏
i=0
1− (1 + sP)t−i
1− (1 + sP)i+1 , (5)
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where N denotes the initial number of cells. The mathematical proof of Equa-
tion (5) is given in Appendix A. Note, that the product can be written in terms
of a q-binomial coefficient (Koekoek et al., 2010),
k−1∏
i=0
1− (1 + sP)t−i
1− (1 + sP)i+1 =
[
t
k
]
1+sP
. (6)
For the case sP = 0, we take the limit of the q-binomial coefficient (e.g. Kac
and Cheung, 2002)
lim
sP→0
[
t
k
]
1+sP
=
(
t
k
)
(7)
and obtain
x0,k(t) = Nµ
k
P(1− (µD + µP))t−k
(
t
k
)
, (8)
which is the result that is also expected if the secondary driver mutations are
neutral and accumulated independently of each other.
Intuitively, the term µkP(1 − (µD + µP))t−k describes the probability of ob-
taining exactly k mutations in t generations. There are different possibilities
when the mutations happen, these possibilities are captured by the binomial
coefficient
(
t
k
)
. Thus, we have a growing polynomial term in t and a declining
exponential term in t, since (1− (µD + µP)) < 1.
In the case of sP 6= 0, the interpretation is similar. Here, additionally the
fitness advantage for secondary driver mutations has to be taken into account.
Since the number of cells with j secondary driver mutations grows with (1+sP)
j ,
also the number of cells that can mutate grows. Hence, the factor (1+sP)
k(k−1)/2
is multiplied to the expression and the binomial coefficient turns into the q-
binomial coefficient.
For cells that have obtained the primary driver mutation and k secondary
driver mutations, the situation is slightly more complex. There are k + 1 dif-
ferent possibilities on how to obtain k secondary driver and the primary driver
mutation, since some of the secondary driver mutations may have occurred be-
fore the primary driver mutation has been acquired whereas others may have
occurred afterwards. Let x
(p)
1,k(t) denote the number of cells with the primary
driver mutation and k secondary driver mutations, when the primary driver
mutation has happened in a cell with p secondary driver mutations. Note that
0 ≤ p ≤ k. The change in the number of cells now depends on p. Using the
abbreviations from Table 3.2.1 to simplify our notation, we have
x
(p)
1,k(t) =
{
νDςDς
k
DPx
(p)
1,k(t− 1) + µPςDςk−1DP x(p)1,k−1(t− 1), if p < k
νDςDς
k
DPx
(p)
1,k(t− 1) + µDςkPx0,k(t− 1), if p = k.
(9)
To express the average number of cells in total we need to sum over all possible
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µP Mutation rate for secondary driver mutations
µD Mutation rate for the primary driver mutation
νP = 1− µD − µP Probability for a cell without the primary driver mutation to not mutate
νD = 1− µP Probability for a cell with the primary driver mutation to not mutate
sP Fitness change of a secondary driver mutation (see (1), (2))
sD+ Fitness advantage of the primary driver mutation (see (1), (2))
sD− Fitness disadvantage of the primary driver mutation (see (1), (2))
sDP Fitness advantage of combination of a secondary driver and the primary
driver mutation
ςP = 1 + sP Fitness according to a secondary driver without the primary driver mutation
ςDP = 1 + sDP Fitness according to the combination of primary and secondary driver mutation
ςD =
1+s+D
1+s−D
≈ 1 + s+D − s−D Fitness according to a primary driver mutation with no secondary driver
Table 1: Summary of our abbreviations
pathways,
x1,k(t) =
k∑
p=0
x
(p)
1,k(t). (10)
In Appendix B, we proof that the analytical solution of Equation (10) is
x1,k(t) =N
k∑
p=0
µDµ
k
P ς
k−p
D ς
(k(k−1)−p(p−1))/2
DP
ς
p(p+1)/2
P∏p−1
n=0(1− ςn+1P )
×
νt−pP
 p∑
r=0
(
−ςt−p+1P
)r
ς
r(r−1)
2
P∏k
n=p(νPς
r
P − νDςDςnDP)
[
p
r
]
ςP

−
k∑
j=p
νj−pP (νDςDς
j
DP)
t−k
k−1∏
m=j
1− ςt−m−1DP
1− ςk−mDP
×
 p∑
r=0
(
−ςj−p+1P
)r
ς
r(r−1)
2
P∏j
n=p(νPς
r
P − νDςDςnDP)
[
p
r
]
ςP

 ,
(11)
if sP 6= 0. The summation over p indicates the different mutational pathways.
An intuitive explanation of this somewhat lengthy equation is given in Appendix
C.
Interestingly, the case for sP = 0 is much more challenging. The underlying
problem is that the normal binomial coefficient cannot be expressed in a sum
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in the way the q-binomial coefficient can be expressed (Koekoek et al., 2010),
[
t
p
]
ςP
=
p−1∏
j=0
1− ςt−jP
1− ςj+1P
=
∑p
r=0 (−ςtP)r (1/ςP)
r(r−1)
2
[
p
r
]
1/ςP∏p−1
j=0(1− ςj+1P )
. (12)
When summing over all generations of the population with p secondary driver
mutations to derive the expression for the population of cells with p+1 secondary
driver mutations, we have to calculate the sum
t−p−1∑
i=0
(ςDς
p
DP)
i
(
t− i− 1
p
)
. (13)
When we go further and try to calculate the expression for the population with
k secondary driver mutations, we need to apply this sum (k−p)-times and hence
we obtain a multi sum,
t−k−1∑
i0=0
(
ςDς
k
DP
)i0 t−k−i0−2∑
i1=0
(
ςDς
k−1
DP
)i1 · · · t−2k+p−i0−i1−···−ik−p−1−1∑
ik−p=0
(ςDς
p
DP)
ik−p
(14)
×
(
t− 2k + p− i0 − i1 − · · · − ik−p−1 − 1
p
)
.
Only an analytical expression for this multi sum would allow a closed solution
of the problem with sP = 0. Also taking the limit sP → 0 of our expression
for sP 6= 0 is a substantial mathematical challenge. However, we can use our
solution for sP 6= 0 for arbitrarily small values of sP. Moreover, numerical
considerations show that the result for sP = 0 is very close to the case of
sP  1.
In Figure 4, the dynamics of the average number of cells with a certain num-
ber of mutations, is shown, both without and with the primary driver mutation.
Simulation results for sP = 0 agree very well with the analytical result obtained
for sP 6= 0.
3.2.2. Distribution of time until cancer initiation
Next, let us calculate the distribution of the time it takes until rapid prolif-
eration occurs. Since we use a multi type, time discrete branching process, we
can make use of the probability generating function to recursively calculate the
probability for a certain cell type cell to be present at a certain time t (Haccou
et al., 2005). Of particular interest is the probability that a tumor initiating cell
is present, i.e. in the example above a cell with the primary driver mutation and
4 secondary driver mutations. Let fi,j(s0,0, . . . , s0,k, s1,0, . . . , s1,k) be the proba-
bility generation function for the cell type xi,j in the branching process described
above. The probability that there is no cell with the primary driver mutation
10
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Figure 4: Dynamics of the number of cells with different number of secondary driver mutations,
without (left) and with (right) the primary driver mutation. Simulation results averaged over
500 independent realizations for sP = 0 (circles) agree almost perfectly with the analytical
result obtained for sP = 10
−5. The bars represent the standard deviation. Cells with no
mutation have a very small relative standard deviation and cells with one mutation (i.e. one
passenger only or the driver only) have a relatively small standard deviation. In contrast,
cells with two passenger mutations for instance have a very broad standard deviation in the
beginning that is approximately four times the average number. Only in few realizations, a
primary driver mutations co-occurs with several secondary drivers, hence the simulation data
for these cases shows a large spread (parameters: N = 500000, sP = 10
−5, sD+ = 0.05,
sD− = 0.1, sDP = 0.015, µP = 2 · 10−5, µD = 5 · 10−6).
and k secondary driver mutations at time t, when the process starts with one
x0,0-cell, can be computed by recursively calculating f(t) := f
◦(t)
0,0 (1, . . . , 1, 0),
where
f
◦(t)
i,j (s) = fi,j(f
◦(t−1)
0,0 (s), . . . , f
◦(t−1)
1,k (s)). (15)
Starting with N cells, we have to consider f(t)N . Thus, the probability that
there is at least one tumor cell at time t is 1 − f(t)N . If we are interested
in the probability τ(t) that there is at least one tumor cell exactly at time t,
we need to subtract the probability, that there has been a tumor cell before
τ(t) = 1− f(t)N − 1 + f(t− 1)N = f(t− 1)N − f(t)N . Figure 5 shows the good
agreement between simulations and the recursive calculation.
The time distribution for low t follows a power law, as shown in the in-
set of Figure 5. The exponent of the power law is approximately 3.4. If all
mutations were neutral, one would expect a lead coefficient of approximately
4 to accumulate five mutations, as derived by Armitage and Doll (1954). In
our case, the curve increases slower. Numerical considerations show that the
main reason for this is that, in contrast to (Armitage and Doll, 1954), we allow
extinction: Many lineages that have accumulated mutations go extinct before
the final, cancer causing mutation arises.
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Figure 5: Comparison between the analytical calculation and simulations of the distribution
until cancer initiation (main panel). Solid lines represents analytic solution. The analytical
calculation and simulations of the model agree very well. This inset illustrates that the time
distribution initially follows a power law with an exponent of ≈ 3.4 shown as a dashed line
(parameters: N = 500000, sP = 10
−5, sD+ = 0.05, sD− = 0.1, sDP = 0.015, µP = 2 · 10−5,
µD = 5 · 10−6, distribution over 20000 independent realizations).
Discussion
Most models in literature assume that each mutation leads to an independent
and steady increase in the cells’ fitness (Beerenwinkel et al., 2007; Bozic et al.,
2010; Gerstung and Beerenwinkel, 2010; Reiter et al., 2013; Michor et al., 2004).
In this context, neutral passenger mutations have no causal impact on cancer
progression. Only recently, some authors have considered passenger mutations
not only as neutral byproducts of the clonal expansion of mutagenic cells, but
as having a deleterious impact on the cells’ fitness (McFarland et al., 2013).
Here, we have described a model in which the fitness of the driver mutation
strongly depends on the number of passenger mutations the cell has acquired.
These passenger mutations, which we have termed secondary driver mutations,
lead only to a small change in fitness or no change in fitness at all. As illus-
trated in Figures 2, 3, and 4, the number of cells stays roughly constant for a
long time before it rapidly increases, despite the fact that mutations occur in the
process permanently. This dynamic effect of cancer initiation is very different
from models in which mutations do not interact with each other. We speculate
that this kind of dynamics can have important implications for diagnosis and
treatment. In principle, the dynamics presented in Figure 2 can also be the
result of one highly advantageous, but very unlikely driver mutation. But in
such a case, cells with the driver mutation should not be present in the popula-
tion before tumorigenesis. This contradicts with current knowledge about the
MYC translocation which has also been detected in humans without lymphoma
(Mu¨ller et al., 1995). This effect is well captured by our model, as shown in
Figure 3.
In some tumors, such as Burkitt Lymphoma, the neoplasms is only diagnosed
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after fast tumor growth has started. In this case, sequencing studies have shown
that several mutations are present at the time of examination (Schmitz et al.,
2012; Alexandrov et al., 2013; Richter et al., 2012; Love et al., 2012). Since the
patients typically do not have any symptoms in before diagnosis of the cancer,
it is possible that some mutations have virtually no direct impact on the cells
fitness. Nevertheless, they are necessary for the initiation of the cancer, as they
indirectly allow the driver mutation to initiate rapid cell growth. This agrees
well with our epistatic model, where (nearly) neutral secondary driver mutations
occur at a fixed rate before the cancer can be diagnosed.
Of course, not all mutations have such an epistatic effect on primary driver
mutations, some might even be considered deleterious (McFarland et al., 2013).
Nevertheless, our work shows that mutations that appear to be neutral in one
context should not only be regarded as a neutral byproduct of the clonal expan-
sion of mutagenic cells. Instead, in some cases passenger mutations can have a
serious impact in cancer initiation, in particular when there are non-trivial inter-
actions between different mutations. In this case the term “passenger” may not
be the most appropriate one. To understand the impact of those interactions
can be essential for a deeper understanding of the initiation of cancer.
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Appendix A. Analytic expression for the average number of cells
without the primary driver mutation at generation t
Appendix A.1. Secondary driver fitness advantage is unequal to zero - k sec-
ondary driver mutations
We first consider the case without the primary driver mutation. We assume
sP 6= 0 (and consequently ςP 6= 1), as discussed in the main text. The rate
change of cells with k secondary driver mutations is
x0,k(t) = νPς
k
Px0,k(t− 1) + µPςk−1P x0,k−1(t− 1), (A.1)
where x0,−1(t) ≡ 0. The solution of (A.1) is formulated in the following theorem:
Theorem 1. For any integer k ≥ 0, the number of cells with k secondary driver
mutations and no primary driver mutation is
x0,k(t) = Nµ
k
Pν
t−k
P ς
k(k−1)/2
P
k−1∏
n=0
1− ςt−nP
1− ςn+1P
. (A.2)
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Proof 1. If (A.2) is a solution, then it must satisfy (A.1). Since solutions for
recursive functions are always unique, (A.2) would be the only solution. Hence,
we proof (A.2) by inserting the equation on the right hand side of (A.1).
νPς
k
Px0,k(t− 1) + µPςk−1P x0,k−1(t− 1)
= νPς
k
PNµ
k
Pν
t−k−1
P ς
k(k−1)/2
P
k−1∏
n=0
1− ςt−n−1P
1− ςn+1P
+ µPς
k−1
P Nµ
k−1
P ν
t−k
P ς
(k−1)(k−2)/2
P
k−2∏
n=0
1− ςt−n−1P
1− ςn+1P
= NµkPν
t−k
P ς
k(k−1)/2
P
(
ςkP
k−1∏
n=0
1− ςt−n−1P
1− ςn+1P
+
k−2∏
n=0
1− ςt−n−1P
1− ςn+1P
)
.
(A.3)
We can write each product as a q-binomial coefficient,
∏k−1
n=0
1−ςt−nP
1−ςn+1P
=
[
t
k
]
ςP
.
Thus, with the q-Pascal rule (Kac and Cheung, 2002)
ςkP
[
t− 1
k
]
ςP
+
[
t− 1
k − 1
]
ςP
=
[
t
k
]
ςP
(A.4)
Equation (A.3) simplifies to
νPς
k
Px0,k(t− 1) + µPςk−1P x0,k−1(t− 1) = NµkPνt−kP ςk(k−1)/2P
k−1∏
n=0
1− ςt−nP
1− ςn+1P
= x0,k(t),
(A.5)
which concludes the proof.
Appendix B. Analytic expression for the average number of cells
with the primary driver mutation at generation t
We now turn to the cells which have obtained the primary driver mutation.
As discussed in the main text, we only look at the case where the fitness change
of the secondary driver mutation is not equal to zero, sP 6= 0. While for cells
without the primary driver mutation there is only one mutational pathway, cells
with the primary driver mutation can be reached via different mutational path-
ways, because cells that get the primary driver mutation might have different
amounts of secondary driver mutations. Hence, we need to sum over all those
possible pathways. Let p be the number of secondary drivers that are present
in the cell which acquires the primary driver mutation. Then x
(p)
1,k(t) denotes
the number of cells with the primary driver mutation and k secondary driver
mutations, when the primary driver mutation has happened in a cell with p
secondary driver mutations (0 ≤ p ≤ k). With this, the total number of cells
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with the primary driver mutation is
x1,k(t) =
k∑
p=0
x
(p)
1,k(t). (B.1)
The change in the number of cells now depends on p. We have
x
(p)
1,k(t) =
{
νDςDς
k
DPx
(p)
1,k(t− 1) + µPςDςk−1DP x(p)1,k−1(t− 1), if p < k
νDςDς
k
DPx
(p)
1,k(t− 1) + µDςkPx0,k(t− 1), if p = k.
(B.2)
The solution of (B.2) is given by the following theorem:
Theorem 2. The average number of cells with the primary driver mutation and
k secondary driver mutations, given that the primary driver mutation happens
in a cell with p secondary driver mutations, is given by
x
(p)
1,k(t) =NµDµ
k
P ς
k−p
D ς
(k(k−1)−p(p−1))/2
DP
ς
p(p+1)/2
P∏p−1
n=0
(
1− ςn+1P
)
×
νt−pP Ψp,k(t)− k∑
j=p
νj−pP
(
νDς
j
DPςD
)t−k
Ψp,j(j)
k−1∏
n=j
1− ςt−n−1DP
1− ςk−nDP
 ,
(B.3)
where the function Ψ is defined
Ψp,k(t) =
p∑
r=0
(
−ςt−p+1P
)r
ς
r(r−1)
2
P
[
p
r
]
ςP∏k
j=p(νPς
r
P − νDςDςjDP)
. (B.4)
Proof 2. Again we proof the theorem by inserting (B.3) in (B.2) and showing
that the equality holds true. We need to distinguish between the two cases as in
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(B.2). First, we proof the theorem for the case p < k.
νDςDς
k
DPx
(p)
1,k(t− 1) + µPςDςk−1DP x(p)1,k−1(t− 1)
= νDςDς
k
DPNµDµ
k
P ς
k−p
D ς
(k(k−1)−p(p−1))/2
DP
ς
p(p+1)/2
P∏p−1
n=0
(
1− ςn+1P
)
×
νt−p−1P Ψp,k(t− 1)− k∑
j=p
νj−pP
(
νDς
j
DPςD
)t−k−1
Ψp,j(j)
k−1∏
n=j
1− ςt−n−2DP
1− ςk−nDP

+ µPςDς
k−1
DP NµDµ
k−1
P ς
k−p−1
D ς
((k−1)(k−2)−p(p−1))/2
DP
ς
p(p+1)/2
P∏p−1
n=0
(
1− ςn+1P
)
×
νt−p−1P Ψp,k−1(t− 1)− k−1∑
j=p
νj−pP
(
νDς
j
DPςD
)t−k
Ψp,j(j)
k−2∏
n=j
1− ςt−n−2DP
1− ςk−n−1DP

= NµDµ
k
P ς
k−p
D ς
(k(k−1)−p(p−1))/2
DP
ς
p(p+1)/2
P∏p−1
n=0
(
1− ςn+1P
)
×
[
νt−p−1P
(
νDςDς
k
DPΨp,k(t− 1) + Ψp,k−1(t− 1)
)− νk−pP (νDςDςkDP)t−kΨp,k(k)
−
k−1∑
j=p
νj−pP Ψp,j(j)
(
νDςDς
j
DP
)t−kςk−jDP k−1∏
n=j
1− ςt−n−2DP
1− ςk−nDP
+
k−2∏
n=j
1− ςt−n−2DP
1− ςk−n−1DP

(B.5)
When we compare (B.3) and (B.5) we see, that the two equations are equal if
νDςDς
k
DPΨp,k(t− 1) + Ψp,k−1(t− 1) = νPΨp,k(t) (B.6)
and
ςk−jDP
k−1∏
n=j
1− ςt−n−2DP
1− ςk−nDP
+
k−2∏
n=j
1− ςt−n−2DP
1− ςk−n−1DP
=
k−1∏
n=j
1− ςt−n−1DP
1− ςk−nDP
(B.7)
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For Equation (B.7), we have
ςk−jDP
k−1∏
n=j
1− ςt−n−2DP
1− ςk−nDP
+
k−2∏
n=j
1− ςt−n−2DP
1− ςk−n−1DP
=
k−1∏
n=j
1− ςt−n−1DP
1− ςk−nDP
⇔ ςk−jDP
k−1∏
n=j
(
1− ςt−n−2DP
)
+
(
1− ςk−jDP
) k−2∏
n=j
(
1− ςt−n−2DP
)
=
k−1∏
n=j
(
1− ςt−n−1DP
)
(B.8)
⇔
(
1− ςk−jDP + ςk−jDP
(
1− ςt−k−1DP
)) k−2∏
n=j
(
1− ςt−n−2DP
)
=
k−1∏
n=j
(
1− ςt−n−1DP
)
⇔
k−1∏
n=j
(
1− ςt−n−1DP
)
=
k−1∏
n=j
(
1− ςt−n−1DP
)
.
For Equation (B.6), we need to insert the definition of Ψ
νDςDς
k
DPΨp,k(t− 1) + Ψp,k−1(t− 1) (B.9)
=
p∑
r=0
(−ςt−pP )r ςr(r−1)/2P [pr
]
ςP
 νDςDςkDP∏k
j=p
(
νPςrP − νDςDςjDP
) + 1∏k−1
j=p
(
νPςrP − νDςDςjDP
)

(B.10)
=
p∑
r=0
(−ςt−pP )r ςr(r−1)/2P [pr
]
ςP
νDςDςkDP + νPςrP − νDςDςkDP∏k
j=p
(
νPςrP − νDςDςjDP
)
 (B.11)
= νP
p∑
r=0
(
−ςt−p+1P
)r
ς
r(r−1)/2
P
[
p
r
]
ςP
(B.12)
= νPΨp,k(t). (B.13)
This concludes the proof for the case p < k. Now we look at the case p = k. We
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have
νDςDς
k
DPx
(k)
1,k(t− 1) + µDςkPx0,k(t− 1) (B.14)
= νDςDς
k
DPNµDµ
k
P
ς
k(k+1)/2
P∏k−1
n=0(1− ςn+1P )
[
νt−k−1P Ψk,k(t− 1)−
(
νDςDς
k
DP
)t−k−1
Ψk,k(k)
]
(B.15)
+ µDς
k
PNµ
k
Pν
t−k−1
P ς
k(k−1)/2
P
k−1∏
n=0
1− ςt−n−1P
1− ςn+1P
(B.16)
= NµDµ
k
P
ς
k(k+1)/2
P∏k−1
n=0(1− ςn+1P )
[
νDςDς
k
DPν
t−k−1
P Ψk,k(t− 1)−
(
νDςDς
k
DP
)t−k
Ψk,k(k) + ν
t−k−1
P
k−1∏
n=0
(
1− ςt−n−1P
)]
.
(B.17)
In order for this to be equal to x
(k)
1,k, we need
νDςDς
k
DPΨk,k(t− 1) +
k−1∏
n=0
(
1− ςt−n−1P
)
= νPΨk,k(t). (B.18)
Analogue to (B.6) this equation holds true if
k−1∏
n=0
(
1− ςt−n−1P
)
= Ψk−1,k(t− 1) =
k∑
r=0
(−ςt−kP )r ςr(r−1)/2P [pr
]
ςP
. (B.19)
By writing the summation as a q-Pochhammer symbol, we have
k∑
r=0
(−ςt−kP )r ςr(r−1)/2P [pr
]
ςP
=
(
ςt−kP ; ςP
)
k
=
k−1∏
n=0
(
1− ςt−k+nP
)
=
k−1∏
n=0
(
1− ςt−n−1P
)
.
(B.20)
This concludes the proof also for p = k.
Appendix C. Intuitive Description of Equation (11)
Here, we try to understand this equation in a more intuitive way. For each
generation t, the number of possibilities to distribute the p secondary driver
mutations over t time steps is given by the q-binomial coefficient
[
t
p
]
ςP
. But the
growth of the cells depends on the time when the secondary driver mutations
are first acquired. Due to fitness advantage, the earlier the mutations have
been acquired, the faster the population grows, and also the sooner the primary
driver mutation can be obtained. As in Equation (5), the effect of the fitness
advantage on the cells without the primary driver mutation itself is captured
by multiplying ς
p(p+1)/2
P . The effect on the primary driver mutation is more
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intricate. To capture this effect, we start from a q-binomial coefficient and
rewrite the q-Pochhammer symbol in the numerator
∏p−1
j=0 1− ςt−jP in terms of
a sum (Koekoek et al., 2010),
[
t
p
]
ςP
=
p−1∏
j=0
1− ςt−jP
1− ςj+1P
=
∑p
r=0 (−ςtP)r (1/ςP)
r(r−1)
2
[
p
r
]
1/ςP∏p−1
j=0(1− ςj+1P )
. (C.1)
To make this resemble the term in the parentheses in the second line of Equation
(11), we divide the numerator by
∏k
j=p(νPς
r
P − νDςDςjDP) and we obtain
∑p
r=0
1∏k
j=p(νPς
r
P−νDςDςjDP)
(−ςtP)r (1/ςP)
r(r−1)
2
[
p
r
]
1/ςP∏p−1
j=0(1− ςj+1P )
. (C.2)
With[
p
r
]
ςP
=
r−1∏
j=0
1− ςp−jP
1− ςj+1P
=
r−1∏
j=0
ςp−2j−1P (1− 1/ςp−jP )
1− 1/ςj+1P
= ς
r(p−r)
P
r−1∏
j=0
1− 1/ςp−jP
1− 1/ςj+1P
= ς
r(p−r)
P
[
p
r
]
1/ςP
(C.3)
Equation (C.2) can be written as
∑p
r=0
1∏k
j=p(νPς
r
P−νDςDςjDP)
(
−ςt−p+1P
)r
ς
r(r−1)
2
P
[
p
r
]
ςP∏p−1
j=0(1− ςj+1P )
. (C.4)
For the numerator of this modified q-binomial coefficient, we introduce the ab-
breviation
Ψp,k(t) =
p∑
r=0
(
−ςt−p+1P
)r
ς
r(r−1)
2
P
[
p
r
]
ςP∏k
j=p(νPς
r
P − νDςDςjDP)
. (C.5)
In terms of this Ψ-function Equation (11) can be written in a more compact
form as
x1,k(t) =N
k∑
p=0
µDµ
k
P ς
k−p
D ς
(k(k−1)−p(p−1))/2
DP
ς
p(p+1)/2
P∏p−1
j=0(1− ςj+1P )
×
νt−pP Ψp,k(t)− k∑
j=p
νj−pP (νDςDς
j
DP)
t−kΨp,j(j)
k−1∏
m=j
1− ςt−m−1DP
1− ςk−mDP
 .
(C.6)
19
References
Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati,
S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Børresen-Dale, A.-
L., Boyault, S., Burkhardt, B., Butler, A. P., Caldas, C., Davies, H. R.,
Desmedt, C., Eils, R., Eyfjo¨rd, J. E., Foekens, J. A., Greaves, M., Hosoda,
F., Hutter, B., Ilicic, T., Imbeaud, S., Imielinski, M., Imielinsk, M., Ja¨ger,
N., Jones, D. T. W., Jones, D., Knappskog, S., Kool, M., Lakhani, S. R.,
Lo´pez-Ot´ın, C., Martin, S., Munshi, N. C., Nakamura, H., Northcott, P. A.,
Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J. V., Puente, X. S.,
Raine, K., Ramakrishna, M., Richardson, A. L., Richter, J., Rosenstiel, P.,
Schlesner, M., Schumacher, T. N., Span, P. N., Teague, J. W., Totoki, Y.,
Tutt, A. N. J., Valde´s-Mas, R., van Buuren, M. M., van ’t Veer, L., Vincent-
Salomon, A., Waddell, N., Yates, L. R., Australian Pancreatic Cancer Genome
Initiative, ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium,
ICGC PedBrain, Zucman-Rossi, J., Futreal, P. A., McDermott, U., Lichter,
P., Meyerson, M., Grimmond, S. M., Siebert, R., Campo, E., Shibata, T.,
Pfister, S. M., Campbell, P. J., Stratton, M. R., 2013. Signatures of mutational
processes in human cancer. Nature 500, 415–421.
Allday, M. J., Dec 2009. How does epstein-barr virus (ebv) complement the
activation of myc in the pathogenesis of burkitt’s lymphoma? Semin Cancer
Biol 19, 366–376.
Antal, T., Krapivsky, P., 2011. Exact solution of a two-type branching process:
models of tumor progression. Journal of Statistical Mechanics: Theory and
Experiment 2011, P08018.
Armitage, P., Doll, R., 1954. The age distribution of cancer and a multi-stage
theory of carcinogenesis. British Journal of Cancer 8, 1–12.
Attolini, C. S.-O., Michor, F., 2009. Evolutionary theory of cancer. Annals of
the New York Academy of Sciences 1168, 23–51.
Barrick, J. E., Lenski, R. E., Dec 2013. Genome dynamics during experimental
evolution. Nature Reviews Genetics 14 (12), 827–39.
Beerenwinkel, N., Antal, T., Dingli, D., Traulsen, A., Kinzler, K. W., Velculescu,
V. E., Vogelstein, B., Nowak, M. A., 2007. Genetic progression and the waiting
time to cancer. PLoS Computational Biology 3, e225.
Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J.,
Varley, J. M., Sep 1998. Cancer phenotype correlates with constitutional tp53
genotype in families with the li-fraumeni syndrome. Oncogene 17 (9), 1061–8.
Bozic, I., Antal, T., Ohtsuki, H., Carter, H., Kim, D., Chen, S., Karchin, R.,
Kinzler, K. W., Vogelstein, B., Nowak, M. A., 2010. Accumulation of driver
and passenger mutations during tumor progression. Proceedings of the Na-
tional Academy of Sciences USA 107, 18545–18550.
20
Campo, E., 2012. New pathogenic mechanisms in burkitt lymphoma. Nat Genet
44 (12), 1288–1289.
Datta, R. S., Gutteridge, A., Swanton, C., Maley, C. C., Graham, T. A., 2013.
Modelling the evolution of genetic instability during tumour progression. Evo-
lutionary Applications 6, 20–33.
de Visser, J. A. G. M., Cooper, T. F., Elena, S. F., Dec 2011. The causes of
epistasis. Proc Biol Sci 278 (1725), 3617–24.
Durrett, R., Foo, J., Leder, K., Mayberry, J., Michor, F., Aug 2010. Evolution-
ary dynamics of tumor progression with random fitness values. Theoretical
Population Biology 78 (1), 54–66.
Durrett, R., Schmidt, D., Schweinsberg, J., 2009. A waiting time problem arising
from the study of multi-stage carcinogenesis. The Annals of Applied Proba-
bility, 676–718.
Elgendy, M., Sheridan, C., Brumatti, G., Martin, S. J., 2011. Oncogenic ras-
induced expression of noxa and beclin-1 promotes autophagic cell death and
limits clonogenic survival. Mol Cell (1), 23–35.
Franke, J., Klo¨zer, A., de Visser, J. A. G. M., Krug, J., 2011. Evolutionary ac-
cessibility of mutational pathways. PLoS Computational Biology 7, e1002134.
Fro¨hling, S., Scholl, C., Levine, R. L., Loriaux, M., Boggon, T. J., Bernard,
O. A., Berger, R., Do¨hner, H., Do¨hner, K., Ebert, B. L., Teckie, S., Golub,
T. R., Jiang, J., Schittenhelm, M. M., Lee, B. H., Griffin, J. D., Stone, R. M.,
Heinrich, M. C., Deininger, M. W., Druker, B. J., Gilliland, D. G., 2007.
Identification of driver and passenger mutations of flt3 by high-throughput
dna sequence analysis and functional assessment of candidate alleles. Cancer
Cell 12, 501–513.
Futreal, P. A., 2007. Backseat drivers take the wheel. Cancer Cell 12, 493–494.
Gerstung, M., Beerenwinkel, N., 2010. Waiting time models of cancer progres-
sion. Mathematical Population Studies 17, 115–135.
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell,
G., Davies, H., Teague, J., Butler, A., Stevens, C., Edkins, S., O’Meara,
S., Vastrik, I., Schmidt, E. E., Avis, T., Barthorpe, S., Bhamra, G., Buck,
G., Choudhury, B., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K.,
Halliday, K., Harrison, R., Hills, K., Hinton, J., Jenkinson, A., Jones, D.,
Menzies, A., Mironenko, T., Perry, J., Raine, K., Richardson, D., Shepherd,
R., Small, A., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates,
A., Cahill, D. P., Louis, D. N., Goldstraw, P., Nicholson, A. G., Brasseur,
F., Looijenga, L., Weber, B. L., Chiew, Y.-E., DeFazio, A., Greaves, M. F.,
Green, A. R., Campbell, P., Birney, E., Easton, D. F., Chenevix-Trench, G.,
Tan, M.-H., Khoo, S. K., Teh, B. T., Yuen, S. T., Leung, S. Y., Wooster, R.,
21
Futreal, P. A., Stratton, M. R., Mar 2007. Patterns of somatic mutation in
human cancer genomes. Nature 446, 153–8.
Haccou, P., Jagers, P., Vatutin, V. A., 2005. Branching processes: variation,
growth, and extinction of populations. Vol. 5. Cambridge University Press,
Cambridge.
Hanahan, D., Weinberg, R., 2000. The hallmarks of cancer. Cell 100, 57–70.
Hoffman, B., Liebermann, D. A., 2008. Apoptotic signaling by c-myc. Oncogene
27, 6462–6472.
Hummel, M., Bentink, S., Berger, H., Klapper, W., Wessendorf, S., Barth, T.
F. E., Bernd, H.-W., Cogliatti, S. B., Dierlamm, J., Feller, A. C., Hansmann,
M.-L., Haralambieva, E., Harder, L., Hasenclever, D., Ku¨hn, M., Lenze, D.,
Lichter, P., Martin-Subero, J. I., Mo¨ller, P., Mu¨ller-Hermelink, H.-K., Ott,
G., Parwaresch, R. M., Pott, C., Rosenwald, A., Rosolowski, M., Schwaenen,
C., Stu¨rzenhofecker, B., Szczepanowski, M., Trautmann, H., Wacker, H.-H.,
Spang, R., Loeffler, M., Tru¨mper, L., Stein, H., Siebert, R., Molecular Mecha-
nisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe,
Jun 2006. A biologic definition of burkitt’s lymphoma from transcriptional
and genomic profiling. New England Journal of Medicine 354 (23), 2419–30.
Iwasa, Y., Michor, F., Komarova, N. L., Nowak, M. A., 2005. Population genet-
ics of tumor supressor genes. Journal of Theoretical Biology 233, 15–23.
Jones, S., Chen, W.-D., Parmigiani, G., Diehl, F., Beerenwinkel, N., Antal,
T., Traulsen, A., Nowak, M. A., Siegel, C., Velculescu, V., Kinzler, K. W.,
Vogelstein, B., Willis, J., Markowitz, S., 2008. Comparative lesion sequencing
provides insights into tumor evolution. Proceedings of the National Academy
of Sciences USA 105, 4283–4288.
Justilien, V., Walsh, M. P., Ali, S. A., Thompson, E. A., Murray, N. R., Fields,
A. P., 2014. The prkci and sox2 oncogenes are coamplified and cooperate to
activate hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 25,
139–151.
Kac, V. G., Cheung, P., 2002. Quantum calculus. Universitext. Springer, New
York.
Knudson, A. G., 1971. Mutation and cancer: Statistical study of retinoblastoma.
Proceedings of the National Academy of Sciences USA 68, 820–823.
Koekoek, R., Lesky, P., Swarttouw, R. F., 2010. Hypergeometric orthogonal
polynomials and their q-analogues. Springer monographs in mathematics.
Springer, Heidelberg.
Lengauer, C., Kinzler, K. W., Vogelstein, B., Dec 1998. Genetic instabilities in
human cancers. Nature 396, 643–9.
22
Lin, C. Y., Love´n, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E.,
Lee, T. I., Young, R. A., 2012. Transcriptional amplification in tumor cells
with elevated c-myc. Cell 151, 56–67.
Love, C., Sun, Z., Jima, D., Li, G., Zhang, J., Miles, R., Richards, K. L.,
Dunphy, C. H., Choi, W. W. L., Srivastava, G., Lugar, P. L., Rizzieri, D. A.,
Lagoo, A. S., Bernal-Mizrachi, L., Mann, K. P., Flowers, C. R., Naresh, K. N.,
Evens, A. M., Chadburn, A., Gordon, L. I., Czader, M. B., Gill, J. I., Hsi,
E. D., Greenough, A., Moffitt, A. B., McKinney, M., Banerjee, A., Grubor,
V., Levy, S., Dunson, D. B., Dave, S. S., 2012. The genetic landscape of
mutations in burkitt lymphoma. Nat Genet 44, 1321–1325.
Luebeck, E. G., Moolgavkar, S. H., 2002. Multistage carcinogenesis and the in-
cidence of colorectal cancer. Proceedings of the National Academy of Sciences
USA 99 (23), 15095–100.
McFarland, C. D., Korolev, K. S., Kryukov, G. V., Sunyaev, S. R., Mirny, L. A.,
Feb 2013. Impact of deleterious passenger mutations on cancer progression.
Proceedings of the National Academy of Sciences USA 110, 2910–5.
Meyer, J. R., Dobias, D. T., Weitz, J. S., Barrick, J. E., Quick, R. T., Lenski,
R. E., 2012. Repeatability and contingency in he evolution of a key innovation
in phage lambda. Science 335, 428–432.
Michor, F., Iwasa, Y., Nowak, M. A., 2004. Dynamics of cancer progression.
Nature Reviews Cancer 4, 197–205.
Mu¨ller, J. R., Janz, S., Goedert, J. J., Potter, M., Rabkin, C. S., Jul 1995. Per-
sistence of immunoglobulin heavy chain/c-myc recombination-positive lym-
phocyte clones in the blood of human immunodeficiency virus-infected homo-
sexual men. Proceedings of the National Academy of Sciences USA 92 (14),
6577–81.
Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green,
D. R., Tessarollo, L., Casellas, R., Zhao, K., Levens, D., 2012. c-myc is a
universal amplifier of expressed genes in lymphocytes and embryonic stem
cells. Cell 151, 68–79.
Nowak, M., Komarova, N. L., Sengupta, A., Jallepalli, P., Shih, I., Vogelstein,
B., Lengauer, C., 2002. The role of chromosomal instability in tumour initia-
tion. Proceedings of the National Academy of Sciences USA 99 (25), 16226–
16231.
Nowak, M. A., Michor, F., Komarova, N. L., Iwasa, Y., 2004. Evolutionary
dynamics of tumor suppressor gene inactivation. Proceedings of the National
Academy of Sciences USA 101, 10635–10638.
Parmigiani, G., Boca, S., Lin, J., Kinzler, K. W., Velculescu, V., Vogelstein,
B., Jan 2009. Design and analysis issues in genome-wide somatic mutation
studies of cancer. Genomics 93, 17–21.
23
Pelengaris, S., Khan, M., Evan, G. I., May 2002. Suppression of myc-induced
apoptosis in beta cells exposes multiple oncogenic properties of myc and trig-
gers carcinogenic progression. Cell 109 (3), 321–34.
Reiter, J. G., Bozic, I., Allen, B., Chatterjee, K., Nowak, M. A., Jan 2013. The
effect of one additional driver mutation on tumor progression. Evolutionary
Applications 6, 34–45.
Richter, J., Schlesner, M., Hoffmann, S., Kreuz, M., Leich, E., Burkhardt, B.,
Rosolowski, M., Ammerpohl, O., Wagener, R., Bernhart, S. H., Lenze, D.,
Szczepanowski, M., Paulsen, M., Lipinski, S., Russell, R. B., Adam-Klages,
S., Apic, G., Claviez, A., Hasenclever, D., Hovestadt, V., Hornig, N., Kor-
bel, J. O., Kube, D., Langenberger, D., Lawerenz, C., Lisfeld, J., Meyer, K.,
Picelli, S., Pischimarov, J., Radlwimmer, B., Rausch, T., Rohde, M., Schil-
habel, M., Scholtysik, R., Spang, R., Trautmann, H., Zenz, T., Borkhardt,
A., Drexler, H. G., Mo¨ller, P., MacLeod, R. A. F., Pott, C., Schreiber, S.,
Tru¨mper, L., Loeffler, M., Stadler, P. F., Lichter, P., Eils, R., Ku¨ppers, R.,
Hummel, M., Klapper, W., Rosenstiel, P., Rosenwald, A., Brors, B., Siebert,
R., ICGC MMML-Seq Project, 2012. Recurrent mutation of the id3 gene in
burkitt lymphoma identified by integrated genome, exome and transcriptome
sequencing. Nature Genetics 44 (12), 1316–20.
Salaverria, I., Siebert, R., 2011. The gray zone between burkitt’s lymphoma and
diffuse large b-cell lymphoma from a genetics perspective. Journal of Clinical
Oncology 29, 1835–1843.
Sander, S., Calado, D. P., Srinivasan, L., Ko¨chert, K., Zhang, B., Rosolowski,
M., Rodig, S. J., Holzmann, K., Stilgenbauer, S., Siebert, R., Bullinger, L.,
Rajewsky, K., Aug 2012. Synergy between pi3k signaling and myc in burkitt
lymphomagenesis. Cancer Cell 22 (2), 167–79.
Schmitz, R., Ceribelli, M., Pittaluga, S., Wright, G., Staudt, L. M., 2014. Onco-
genic mechanisms in burkitt lymphoma. Cold Spring Harb Perspect Med 4 (2).
Schmitz, R., Young, R. M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M.,
Wright, G., Shaffer, A. L., Hodson, D. J., Buras, E., Liu, X., Powell, J.,
Yang, Y., Xu, W., Zhao, H., Kohlhammer, H., Rosenwald, A., Kluin, P.,
Mu¨ller-Hermelink, H. K., Ott, G., Gascoyne, R. D., Connors, J. M., Rimsza,
L. M., Campo, E., Jaffe, E. S., Delabie, J., Smeland, E. B., Ogwang, M. D.,
Reynolds, S. J., Fisher, R. I., Braziel, R. M., Tubbs, R. R., Cook, J. R.,
Weisenburger, D. D., Chan, W. C., Pittaluga, S., Wilson, W., Waldmann,
T. A., Rowe, M., Mbulaiteye, S. M., Rickinson, A. B., Staudt, L. M., Oct
2012. Burkitt lymphoma pathogenesis and therapeutic targets from structural
and functional genomics. Nature 490 (7418), 116–20.
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., Lowe, S. W., 1997.
Oncogenic ras provokes premature cell senescence associated with accumula-
tion of p53 and p16ink4a. Cell 88, 593–602.
24
Sjo¨blom, T., Jones, S., Wood, L., Parsons, D., Lin, J., Barber, T., Mandelker,
D., Leary, R., Ptak, J., Silliman, N., Szabo, S., Buckhaults, P., Farrell, C.,
Meeh, P., Markowitz, S., Willis, J., Dawson, D., Willson, J., Gazdar, A.,
Hartigan, J., Wu, L., Liu, C., Parmigiani, G., Park, B., Bachman, K., Pa-
padopoulos, N., Vogelstein, B., Kinzler, K., Velculescu, V., 2006. The con-
sensus coding sequences of human breast and colorectal cancers. Science 314,
268–274.
Szappanos, B., Kova´cs, K., Szamecz, B., Honti, F., Costanzo, M., Baryshnikova,
A., Gelius-Dietrich, G., Lercher, M. J., Jelasity, M., Myers, C. L., Andrews,
B. J., Boone, C., Oliver, S. G., Pa´l, C., Papp, B., Jul 2011. An integrated
approach to characterize genetic interaction networks in yeast metabolism.
Nature Genetics 43 (7), 656–62.
Szendro, I. G., Franke, J., de Visser, J. A. G. M., Krug, J., 2013. Predictability
of evolution depends nonmonotonically on population size. Proceedings of the
National Academy of Sciences USA 110, 571–576.
Varley, J., 2003. Tp53, hchk2, and the li-fraumeni syndrome. Methods Mol Biol
222, 117–29.
Vogelstein, B., Kinzler, K., 2004. Cancer genes and the pathways they control.
Nature Medicine 10, 789–799.
Wang, C., Tai, Y., Lisanti, M. P., Liao, D. J., 2011. c-myc induction of pro-
grammed cell death may contribute to carcinogenesis: a perspective inspired
by several concepts of chemical carcinogenesis. Cancer Biology and Therapy
11, 615–626.
Weinreich, D. M., Watson, R., Chao, L., 2005. Perspective: sign epistasis and
genetic constraint on evolutionary trajectories. Evolution 56 (6), 1165–1174.
Wodarz, D., Komarova, N., 2005. Computational biology of cancer: Lecture
notes and mathematical modeling. World Scientific Publishing.
Wolf, J. B., Brodie, E. D., Wade, M. J., 2000. Epistasis and the evolutionary
process. Oxford University Press, USA.
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjoblom, T., Leary, R. J.,
Shen, D., Boca, S. M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso,
Z., Ustyanksky, V., Nikolskaya, T., Nikolsky, Y., Karchin, R., Wilson, P. A.,
Kaminker, J. S., Zhang, Z., Croshaw, R., Willis, J., Dawson, D., Shipitsin, M.,
Willson, J. K. V., Sukumar, S., Polyak, K., Park, B. H., Pethiyagoda, C. L.,
Pant, P. V. K., Ballinger, D. G., Sparks, A. B., Hartigan, J., Smith, D. R.,
Suh, E., Papadopoulos, N., Buckhaults, P., Markowitz, S. D., Parmigiani,
G., Kinzler, K. W., Velculescu, V. E., Vogelstein, B., 2007. The genomic
landscapes of human breast and colorectal cancers. Science 318 (5853), 1108–
1113.
25
Zech, L., Haglund, U., Nilsson, K., Klein, G., 1976. Characteristic chromosomal
abnormalities in biopsies and lymphoid-cell lines from patients with burkitt
and non-burkitt lymphomas. Int J Cancer 17, 47–56.
26
